                         SEQUENCE LISTING

<110>  Commissariat  l'Energie Atomique
 
<120>  Cyclopeptides utilisables en tant qu'inhibiteurs d'enzymes 
       protases du type MMP

<130>  SP32081 (PCT) / FG

<140>  PCT/EP2009/XXXX
<141>  2009-06-10

<150>  FR 08/53851
<151>  2008-06-10

<160>  37    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  unidentified

<400>  1

Gly Pro Gln Gly Leu Leu Gly Ala 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  unidentified

<400>  2

Ala Pro Gln Gly Ile Ala Gly Gln 
1               5               


<210>  3
<211>  8
<212>  PRT
<213>  unidentified

<400>  3

Gly Pro Gln Gly Leu Ala Gly Gln 
1               5               


<210>  4
<211>  8
<212>  PRT
<213>  unidentified

<400>  4

Gly Pro Leu Gly Ile Ala Gly Ile 
1               5               


<210>  5
<211>  8
<212>  PRT
<213>  unidentified

<400>  5

Gly Pro Glu Gly Leu Arg Val Gly 
1               5               


<210>  6
<211>  8
<212>  PRT
<213>  unidentified

<400>  6

Tyr Glu Ala Gly Leu Gly Val Val 
1               5               


<210>  7
<211>  8
<212>  PRT
<213>  unidentified

<400>  7

Ala Gly Leu Gly Val Val Glu Arg 
1               5               


<210>  8
<211>  8
<212>  PRT
<213>  unidentified

<400>  8

Ala Gly Leu Gly Ile Ser Ser Thr 
1               5               


<210>  9
<211>  8
<212>  PRT
<213>  unidentified

<400>  9

Gly Ala Met Phe Leu Glu Ala Ile 
1               5               


<210>  10
<211>  8
<212>  PRT
<213>  unidentified

<400>  10

Ile Pro Glu Asn Phe Phe Gly Val 
1               5               


<210>  11
<211>  8
<212>  PRT
<213>  unidentified

<400>  11

Thr Glu Gly Glu Ala Arg Gly Ser 
1               5               


<210>  12
<211>  6
<212>  PRT
<213>  unidentified


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X reprsente une 3-cyclohexyl alanine (Cha)

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X reprsente un acide alpha amino-butyrique (Abu)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X reprsente Cys(Me)

<400>  12

Pro Xaa Xaa Xaa His Ala 
1               5       


<210>  13
<211>  6
<212>  PRT
<213>  unidentified


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X reprsente une 3 cyclohexyl alanine (Cha)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X reprsente Cys(Me)

<400>  13

Pro Xaa Gly Xaa His Ala 
1               5       


<210>  14
<211>  8
<212>  PRT
<213>  unidentified

<400>  14

Pro Pro Gly Ala Tyr His Gly Ala 
1               5               


<210>  15
<211>  7
<212>  PRT
<213>  unidentified

<400>  15

Pro Gln Gly Leu Glu Ala Lys 
1               5           


<210>  16
<211>  7
<212>  PRT
<213>  unidentified


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X reprsente une norvaline (Nva)

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  X reprsente un N-3(2,4-dinitrophnyl)-L-2,3-diaminopropyle (Dpa)

<400>  16

Pro Leu Ala Xaa Xaa Ala Arg 
1               5           


<210>  17
<211>  8
<212>  PRT
<213>  unidentified

<400>  17

Arg Val Gly Phe Tyr Glu Ser Asp 
1               5               


<210>  18
<211>  8
<212>  PRT
<213>  unidentified

<400>  18

Leu Leu Ser Ala Leu Val Glu Thr 
1               5               


<210>  19
<211>  8
<212>  PRT
<213>  unidentified

<400>  19

Glu Ala Ile Pro Met Ser Ile Pro 
1               5               


<210>  20
<211>  8
<212>  PRT
<213>  unidentified

<400>  20

Ile Ala Gly Arg Ser Leu Asn Pro 
1               5               


<210>  21
<211>  8
<212>  PRT
<213>  unidentified

<400>  21

Lys Pro Gln Gln Phe Phe Gly Leu 
1               5               


<210>  22
<211>  8
<212>  PRT
<213>  unidentified

<400>  22

Asp Val Ala Gln Phe Val Leu Thr 
1               5               


<210>  23
<211>  8
<212>  PRT
<213>  unidentified

<400>  23

Asp Thr Leu Glu Val Met Arg Lys 
1               5               


<210>  24
<211>  8
<212>  PRT
<213>  unidentified

<400>  24

Asp Val Gly His Phe Arg Thr Phe 
1               5               


<210>  25
<211>  8
<212>  PRT
<213>  unidentified

<400>  25

Asp Ser Gly Gly Phe Met Leu Thr 
1               5               


<210>  26
<211>  8
<212>  PRT
<213>  unidentified

<400>  26

Arg Val Ala Glu Met Arg Gly Glu 
1               5               


<210>  27
<211>  8
<212>  PRT
<213>  unidentified

<400>  27

Asp Leu Gly Arg Phe Gln Thr Phe 
1               5               


<210>  28
<211>  8
<212>  PRT
<213>  unidentified

<400>  28

Pro Phe Ser Pro Leu Val Ala Thr 
1               5               


<210>  29
<211>  8
<212>  PRT
<213>  unidentified

<400>  29

Ala Pro Gly Asn Ala Ser Glu Ser 
1               5               


<210>  30
<211>  8
<212>  PRT
<213>  unidentified

<400>  30

Phe Ser Ser Glu Ser Lys Arg Glu 
1               5               


<210>  31
<211>  8
<212>  PRT
<213>  unidentified

<400>  31

Pro Pro Glu Glu Leu Lys Phe Gln 
1               5               


<210>  32
<211>  8
<212>  PRT
<213>  unidentified

<400>  32

Gly Pro Pro Gly Val Val Gly Pro 
1               5               


<210>  33
<211>  8
<212>  PRT
<213>  unidentified

<400>  33

Gly Pro Pro Gly Leu Arg Gly Glu 
1               5               


<210>  34
<211>  8
<212>  PRT
<213>  unidentified

<400>  34

Gly Pro Gly Gly Val Val Gly Pro 
1               5               


<210>  35
<211>  8
<212>  PRT
<213>  unidentified

<400>  35

Ile Pro Gln Asn Phe Phe Gly Val 
1               5               


<210>  36
<211>  8
<212>  PRT
<213>  unidentified

<400>  36

Pro Pro Gly Ala Tyr His Gly Ala 
1               5               


<210>  37
<211>  7
<212>  PRT
<213>  unidentified


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X reprsente Cys(p-OMeBz)

<400>  37

Pro Leu Ala Xaa Trp Ala Arg 
1               5           


